Background Despite the availability of several potent antithrombotic agents, the optimal antiplatelet regimen in elective patients undergoing complex percutaneous coronary interventions is still debated. Aim of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial will be to assess the safety and efficacy of routine usage of the glycoprotein llb/llls inhibitor eptifibatide in patients already treated with aspirin and clopidogrel and undergoing implantation of at least two drug-eluting stents in the same lesion, thus identifying a clinically stable but anatomically complex patient subset. Design This will be a single-blind, placebo-controlled multicenter randomized trial. Methods Patients with stable coronary artery disease, who are undergoing percutaneous coronary intervention by means of implantation of greater than 33mm of drug-eluting stents (e.g. with two 23-mm drug-eluting stents or one 32-mm and one 12-mm drug-eluting stent), will be randomized, after administration of aspirin and clopidogrel (600mg loading dose recommended), to eptifibatide and unfractioned heparin according to the ESPRIT protocol or placebo and unfractioned heparin. Blood draws for creatine kinase-MB mass, total creatine kinase, and cardiac troponin levels will be taken at baseline, 6 and 12 h postprocedurally. Patients will be followed for clinical events by direct visit or phone contact up to 6 months. The primary endpoint of the study will be the rate of abnormal values of creatine kinaseMB mass after percutaneous coronary intervention. Secondary endpoints will be the composite of cardiac death, nonfatal myocardial infarction, urgent target vessel revascularization, and thrombotic bailout glycoprotein Ilb/Illa inhibitor therapy within 180 days, and in-hospital, 1-month and 6-month major adverse cardiovascular events, defined as the composite of cardiac death, nonfatal myocardial infarction or urgent target vessel revascularization. Implications The INtegrilin plus STenting to Avoid myocardial Necrosis Trial study will test for the first time the beneficial impact of routine glycoprotein Ilb/Illa inhibition on top of dual oral antiplatelet treatment in clinically stable yet anatomically complex patients undergoing drug-eluting stents implantation. Results of this single-blind randomized trial will provide important insights to improve the management strategy of patients and outcomes in the current drug-eluting stents era.

Biondi Zoccai, G., Valgimigli, M., Sheiban, I., Margheri, M., Marzocchi, A., Prati, F., et al. (2008). A randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial. JOURNAL OF CARDIOVASCULAR MEDICINE, 9(9), 957-962 [10.2459/JCM.0b013e3282ffd3a6].

A randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial

ROMEO, FRANCESCO;SANGIORGI, GIUSEPPE
2008-01-01

Abstract

Background Despite the availability of several potent antithrombotic agents, the optimal antiplatelet regimen in elective patients undergoing complex percutaneous coronary interventions is still debated. Aim of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial will be to assess the safety and efficacy of routine usage of the glycoprotein llb/llls inhibitor eptifibatide in patients already treated with aspirin and clopidogrel and undergoing implantation of at least two drug-eluting stents in the same lesion, thus identifying a clinically stable but anatomically complex patient subset. Design This will be a single-blind, placebo-controlled multicenter randomized trial. Methods Patients with stable coronary artery disease, who are undergoing percutaneous coronary intervention by means of implantation of greater than 33mm of drug-eluting stents (e.g. with two 23-mm drug-eluting stents or one 32-mm and one 12-mm drug-eluting stent), will be randomized, after administration of aspirin and clopidogrel (600mg loading dose recommended), to eptifibatide and unfractioned heparin according to the ESPRIT protocol or placebo and unfractioned heparin. Blood draws for creatine kinase-MB mass, total creatine kinase, and cardiac troponin levels will be taken at baseline, 6 and 12 h postprocedurally. Patients will be followed for clinical events by direct visit or phone contact up to 6 months. The primary endpoint of the study will be the rate of abnormal values of creatine kinaseMB mass after percutaneous coronary intervention. Secondary endpoints will be the composite of cardiac death, nonfatal myocardial infarction, urgent target vessel revascularization, and thrombotic bailout glycoprotein Ilb/Illa inhibitor therapy within 180 days, and in-hospital, 1-month and 6-month major adverse cardiovascular events, defined as the composite of cardiac death, nonfatal myocardial infarction or urgent target vessel revascularization. Implications The INtegrilin plus STenting to Avoid myocardial Necrosis Trial study will test for the first time the beneficial impact of routine glycoprotein Ilb/Illa inhibition on top of dual oral antiplatelet treatment in clinically stable yet anatomically complex patients undergoing drug-eluting stents implantation. Results of this single-blind randomized trial will provide important insights to improve the management strategy of patients and outcomes in the current drug-eluting stents era.
2008
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE
English
antithrombocytic agent; creatine kinase MB; eptifibatide; fibrinogen receptor; peptide; article; bioassay; blood; clinical trial; coronary artery disease; drug antagonism; drug eluting stent; female; human; male; methodology; multicenter study; randomized controlled trial; single blind procedure; transluminal coronary angioplasty; Angioplasty, Transluminal, Percutaneous Coronary; Coronary Artery Disease; Creatine Kinase, MB Form; Drug-Eluting Stents; Endpoint Determination; Female; Humans; Male; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Research Design; Single-Blind Method
Drug-eluting stent; Glycoprotein ilb/iiia inhibitors; Percutaneous coronary intervention; Study design
Biondi Zoccai, G., Valgimigli, M., Sheiban, I., Margheri, M., Marzocchi, A., Prati, F., et al. (2008). A randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial. JOURNAL OF CARDIOVASCULAR MEDICINE, 9(9), 957-962 [10.2459/JCM.0b013e3282ffd3a6].
Biondi Zoccai, G; Valgimigli, M; Sheiban, I; Margheri, M; Marzocchi, A; Prati, F; Vischi, M; Lettieri, C; Violin, R; Sardella, G; Stabile, A; Clementi, F; Romeo, F; Colombo, A; Sangiorgi, G
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/57811
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact